Current Clinical Trials

PREFERENCE: A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes
  1. Andrew Rubin, MD
    Andrew Rubin, MD
  2. Rancho Mirage, CA
  3. study started September 2024
  4. Andrew Rubin, MD
  5. Accepting new patients

Description

Summary

All US sites with randomized subjects on the 70033093AFL3002 LIBREXIA-AF study are given the opportunity to participate on the Preference Survey study. Preference information is used in healthcare research to complement clinical data and increase the understanding of patients’ and physicians’ willingness to make benefit-risk tradeoffs. The current study (70033093AFL0001; hereafter referred to as the Preference Study) is a prospective, non-interventional study that aims to collect data on physician and patient preferences for anticoagulant therapy for atrial fibrillation (AF) to support patient-centered benefit-risk assessment.

Official Title

PREFERENCE: A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes

Keywords

Atrial Fibrillation

Eligibility

All US sites participating in the Phase 3 study are eligible to participate in this preference study. Once a site agrees to participate in the preference study, at least one study investigator from the site has to participate in the physician survey. In addition, all patients at the site, including those already randomized in the Phase 3 study, are eligible to participate in the Preference study. Prior to data collection for the Preference Study, patients must sign an informed consent form (ICF)... more
less

All US sites participating in the Phase 3 study are eligible to participate in this preference study. Once a site agrees to participate in the preference study, at least one study investigator from the site has to participate in the physician survey. In addition, all patients at the site, including those already randomized in the Phase 3 study, are eligible to participate in the Preference study. Prior to data collection for the Preference Study, patients must sign an informed consent form (ICF) allowing data collection in accordance with local requirements and/or sponsor policy. Patients who are already randomized in the Phase 3 study before initiation of the Preference Study will be offered the Preference Study ICF at their first in-patient clinic visit after the survey becomes available at the site. For patients who are yet to be randomized in the Phase 3 study at the time of Preference Study initiation, the ICF will be offered at the time of screening or randomization.

Lead Scientists at Eisenhower Health

Andrew Rubin, MD
Andrew Rubin, MD holds Board Certifications in Cardiac Electrophysiology, Cardiovascular Disease and Internal Medicine. After completing his internship and residency at The Grad Hospital/University of Pennsylvania, Dr. Rubin earned a Cardiology fellowship at Temple University Hospital and an Electrophysiology fellowship at Lankenau Hospital. With regard to patient care, Dr. Rubin is heavily influenced by his upbringing. “I was raised in an environment where seeing a doctor was a big dea... more
less

Andrew Rubin, MD holds Board Certifications in Cardiac Electrophysiology, Cardiovascular Disease and Internal Medicine. After completing his internship and residency at The Grad Hospital/University of Pennsylvania, Dr. Rubin earned a Cardiology fellowship at Temple University Hospital and an Electrophysiology fellowship at Lankenau Hospital.

With regard to patient care, Dr. Rubin is heavily influenced by his upbringing. “I was raised in an environment where seeing a doctor was a big deal. I appreciate the possible overwhelming atmosphere of a doctor’s office and don’t take for granted what a person is thinking when they meet with me,” states Dr. Rubin. “I see people who are usually in some state of fear — after all, their heart is not working properly and they are scared.”  In addition, Dr. Rubin was in a severe car accident in the 1980s and was in and out of the hospital over a couple of years. “I have seen medicine from the other side — as a patient — when you are not well, you are looking for someone to show you empathy,” says Dr. Rubin.  At the same time, Dr. Rubin is very up front regarding his patient’s responsibility in their own health care journey. “If you don’t take care of your body, it doesn’t matter what a physician does for you. If you smoke, don’t exercise and eat a lot of sugar, you are not going to regain wellness.”

At Eisenhower Medical Center, Dr. Rubin serves as co-director of Electrophysiology where he oversees Cardiac Research and the Pacemaker Defibrillator Clinic at Eisenhower Desert Cardiology Center, and previously served as Section Chief of Cardiology. He is also director of Cardiology teaching for the Internal Medicine and Family Medicine Residency Programs at Eisenhower Medical Center. He has been honored as the Eisenhower Medical Center Auxiliary Physician of the Year in 2009 and Eisenhower Medical Center Physician of the Month in January 2010.

Furthermore, Dr. Rubin is President and CEO of Genetic Research Institute of the Desert and served as a member of the Steering Committee of the National Institutes of Health Atrial Fibrillation Trial.

Working as principal or co-investigator for more than 63 clinical investigations related to cardiac arrhythmias, Dr. Rubin has peer reviewed more than 18 publications, two book chapters and numerous abstract presentations and clinical presentations. Dr. Rubin was born, raised and trained in Philadelphia. He came to the desert in 1994 after practicing in an academic electrophysiology practice in the Philadelphia region following his training. He remains active in the field of clinical research with special interest in atrial fibrillation and anticoagulation.

Clinical Study Details

  1. Accepting new patients
  2. study started September 2024
  3. Non-Interventional
  4. December 04, 2024